Kommanditgesellschaft auf Aktien

(redirected from KGaA)
Also found in: Acronyms.

Kommanditgesellschaft auf Aktien

Abbreviated KgAA. A corporate structure in Germany equivalent to a master limited partnership.
References in periodicals archive ?
"We are very pleased with this collaboration, as our companies bring a perfectly matching set of know-how to the table," said Kai Beckmann, CEO Performance Materials and member of the Executive Board of Merck KGaA, Darmstadt, Germany.
Merck KGaA, Darmstadt, Germany, will acquire Intermolecular through its wholly owned subsidiary EMD Group Holding II, Inc.
"We are thrilled that Merck KGaA is collaborating with Iktos to further accelerate its drug discovery capabilities," said Yann Gaston-Mathe, president and chief executive officer, Iktos.
It is a part of Merck KGaA's R&D strategy to improve drug discovery with strategic technology-focused collaborations.
Merck KGaA, Darmstadt, Germany will receive an upfront payment of 300 million (260 million) and is eligible for potential development milestone payments of up to 500 million (440 million) triggered by data from the M7824 lung cancer programme.
It is also under further clinical evaluation across a range of tumour types under a global strategic alliance between Merck KGaA, Darmstadt, Germany, and Pfizer.
Thanks to expansion of the TANC in Shanghai, Merck KGaA, Darmstadt, Germany, can meet the growing number of customer requests for close collaboration and technical consultation on the entire product portfolio of pigments and functional materials and especially on how to integrate these products in new technologies.
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S.
For more information, visit www.astellas.com/en About Merck KGaA, Darmstadt, Germany
Siegwerk produced the respective pearlescent inks with pigments from Merck KGaA. The RGB process called for a totally new reproduction technology in the prepress phase.
NORDIC BUSINESS REPORT-April 19, 2011--Autoliv teams with Hella KGaA Hueck on vision technologies(C)2011 M2 COMMUNICATIONS http://www.m2.com
Fast Forward, LLC, a wholly-owned subsidiary of the National Multiple Sclerosis Society (NMSS), and EMD Serono, Inc., an affiliate of Merck KGaA (Darmstadt, Germany), have committed $3 million in 2009 to support innovative early-stage projects directed toward developing therapies to prevent, treat, or reverse nervous-system damage in MS.